GNI Group Ltd. (FRA:3G6)

Market Cap	910.12M +3.1%
Revenue (ttm)	147.52M +17.7%
Net Income	-32.77M
EPS	-0.61
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	12.80
Previous Close	13.40
Day's Range	12.80 - 12.80
52-Week Range	11.90 - 19.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About GNI Group

GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products. It also develops ETUARY which is in Phase III clinical trial for...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 990
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3G6

Financial Performance

Financial numbers in JPY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 28, 2026

Data Sources Report a data error